



For Immediate Release

Ausbiotech 2019 Conference Presentation

MELBOURNE, Australia, 30 October 2019: Dimerix Limited (ASX: DXB), a clinical-stage biopharmaceutical company, is pleased to provide a copy of the presentation from the Ausbiotech 2019 Conference today.

For further information, please visit our website at www.dimerix.com or contact:

Dr Nina Webster, Dimerix Limited
Chief Executive Officer & Managing Director
Tel: +61 1300 813 321
E: investor@dimerix.com

—END—

About Dimerix

Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets. Dimerix is currently developing its proprietary product DMX-200 for both Diabetic Kidney Disease and Focal Segmental Glomerulosclerosis (FSGS). DMX-200 was identified using Dimerix' proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Receptor-HIT is licensed non-exclusively to Excellerate Bioscience, a UK-based pharmacological assay service provider with a worldwide reputation for excellence in the field of molecular and cellular pharmacology.

About DMX-200

DMX-200 is the adjunct therapy of a chemokine receptor (CCR2) antagonist administered to patients already receiving irbesartan, an angiotensin II type I (AT1) receptor blocker and the standard of care treatment for kidney disease. DMX-200 has granted patents in various territories until 2032.

In 2017, Dimerix completed its first Phase 2a study in patients with a range of chronic kidney diseases. No significant adverse safety events were reported, and all study endpoints were achieved. In a subsequent sub-group analysis, significant clinical efficacy signals were seen in the diabetic group.

DMX-200 administered to patients already taking irbesartan reduced proteinuria levels by a further 36%. This reduction in proteinuria is highly correlated with improved renal function and delay in kidney failure and dialysis. The compelling results from this study prompted the decision to initiate two different clinical studies in 2018: one for patients with Diabetic Kidney Disease; and the second for patients with another form of kidney disease, Focal Segmental Glomerulosclerosis (FSGS).

Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs

Dimerix HQ
425 Smith St, Fitzroy 3065
Victoria, Australia
T. 1300 813 321
E. investor@dimerix.com



FSGS is a serious and rare disease that attacks the kidney's filtering units (glomeruli) causing serious scarring which leads to permanent kidney damage and kidney failure and for which there is a recognised medical need for a new or improved treatment. FSGS affects both children and adults.

DMX-200 for FSGS has been granted Orphan Drug Designation by the FDA and EMA. Orphan Drug Designation is granted to support the development of products for rare diseases and qualifies Dimerix for various development incentives including: seven years (FDA) and ten years (EMA) of market exclusivity if regulatory approval is received, exemption from certain application fees, and an abbreviated regulatory pathway to approval.

About DMX-700

COPD is a progressive and life-threatening lung disease. The primary cause of COPD is exposure to tobacco smoke (either active smoking or secondary smoke), however is also caused by exposure to indoor and outdoor air pollution, occupational dusts and fumes and long-term asthma. COPD is the fourth-leading cause of death in the world and although treatments exist to improve the symptoms of COPD, there is currently no way to slow progression of the condition or cure it. Moreover, among the top five causes of death globally, this disease is the only one with increasing mortality rates. The global COPD treatment market was valued at US\$14 billion in 2017 and is projected to increase at a compound annual growth rate of 4.9% to 2026.

Initial studies have been completed, and Dimerix has completed a key step in securing ownership over what it believes is an important new drug discovery by lodging a provisional patent application for DMX-700. Over the next 12 months Dimerix will conduct further proof of concept studies to perform the value added verification in support of a robust product development pathway and patent position.

Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs

Dimerix HQ
425 Smith St, Fitzroy 3065
Victoria, Australia
T. 1300 813 321
E. investor@dimerix.com

Dimerix

Target indications: a hot area for big pharma?

Ausbiotech
30 October 2019



Forward looking statements

This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Dimerix to be materially different from the statements in this presentation.

Actual results could differ materially depending on factors such as the availability of resources, the results of clinical studies, the timing and effects of regulatory actions, the strength of competition, the outcome of legal proceedings and the effectiveness of patent protection.

Corporate snapshot (ASX:DXB)

Financial information

Share price (29Oct19)	A\$0.11
52 week low / high	A\$0.07 / 0.15
Shares on issue	158.8m

Market Capitalisation

A\$17.5 million


Cash (as at 30Sep19)	A\$1.99 million*
Debt (as at 30Sep19)	\$0

Enterprise value

A\$15.5 million

**does not include R&D tax rebate of \$1.2 million received*

Share price performance



Executive summary

Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs using its scalable, proprietary platform technology

Three product candidates in active development:

- DMX-200 in two Phase 2 studies:

- 1. Focal Segmental Glomerulosclerosis (FSGS)**
- 2. Diabetic Kidney Disease**

Clinical read-out
for both studies
in Q2 2020

- DMX-700 preparing for clinical studies:

- 3. Chronic Obstructive Pulmonary Disease (COPD)**

In clinic within
2 years


Receptor-HIT platform technology:

- Other potential pipeline candidates under assessment
- Receptor-HIT assay licensed globally

Additional potential
pipeline candidates
identified


A pipeline of drugs identified using Receptor-HIT

Targeting different GPCR receptor pairs



Strategic Fit

- Dimerix is developing a **commercial pipeline** of drugs for G Protein-Coupled Receptors (GPCR) largely targeting chemokine pathway diseases with a **clear unmet need**
- Dimerix can utilise its current core **competencies** and **capabilities** to execute on the disclosed opportunities
- Dimerix has identified **new uses** for existing drugs to drive the **discovery** of new drugs and research programs
- Dimerix has **multiple products** in its pipeline, at different development stages, **diversifying** risk and increasing potential future sources of revenue



DMX-200 Overview

DMX-200 overview

DMX-200: a small molecule known as propagermanium

- Twice daily, capsule administration
- Administered to patients already on standard of care treatment (Irbesartan)
- Never been approved by a regulatory authority for clinical use in the US, Europe or Australia

New Chemical Entity
Never been FDA
approved

DMX-200 has completed a Phase 1 and a Phase 2a clinical studies in kidney disease, providing clinically and statistically significant results:

- **36% reduction in proteinuria (in addition to the 24% reduction seen with irbesartan)**

Compelling data encouraged Dimerix to progress into 2 Phase 2 clinical studies:

- Phase 2 in Focal Segmental Glomerulosclerosis (FSGS) – an orphan indication
- Phase 2 in Diabetic Kidney Disease



*NCE can attract 5 years exclusivity in US and EU
(7 years in US and 10 years in EU for Orphan Drugs)

Phase 2 trial in Diabetic Kidney Disease

DMX-200 in Diabetic Kidney Disease (DKD)

Progressive disease, leading to kidney failure and blood dialysis

23 million diagnosed diabetics in the US

Diabetes incidence estimated to grow 54% by 2040

>20% of diabetics had kidney disease

- Double-blind, randomised, placebo-controlled, crossover study evaluating the safety and efficacy of DMX-200 in patients with diabetic kidney disease who are receiving a stable dose of Irbesartan



Group 1 (n=20)

Group 2 (n=20)

Study period 1
12 weeks

DMX-200

Washout
6 weeks

Study Period 2
12 weeks

Placebo

DMX-200


Results

Irbesartan 300mg


Study completion anticipated Q2 2020 (calendar year)

- Standard of care (Irbesartan 300mg) US market = >4 million scripts in 2017 (US\$2 billion)
- Assumed ~50% will require additional /adjunct treatment
- Addressable market = >\$1 billion/year

Phase 2a trial in FSGS




- Double-blind, randomised, placebo-controlled, crossover study evaluating the safety and efficacy of DMX-200 in patients with FSGS who are receiving a stable dose of Irbesartan



- ~120,000 sufferers in US; ~10% receive of orphan disease sufferers treatment
- Average orphan drug = ~US\$7,000/month
- Addressable market = US\$1 billion/year

DMX-200 regulatory overview





Introduction to DMX-700

What is COPD?

DMX-700 in Chronic Obstructive Pulmonary Disease (COPD)

Progressive & life-threatening lung disease affecting individuals of all ages

caused by: tobacco smoke, air pollution, occupational dust/fumes, long-term asthma

COPD limits pulmonary airflow that is not fully reversible

Usually progressive with an abnormal inflammatory response

No cure available & existing treatments aimed at relieving symptoms only

4th leading cause of death worldwide


Among the top 5 causes of death, COPD is the only one with increasing mortality rates

COPD incidence increasing due to aging populations and continued smoking prevalence

3.17 million deaths caused by COPD in 2015
(5% of all deaths globally that year)



COPD landscape



Global Initiatives

- World Health Organization (WHO)
- COPD Foundation
- American Thoracic Society
- Centers for Disease Control & Prevention (CDC)
- National Institute of Health (NIH)

All working towards raising COPD awareness in the population

2018 – FDA Guidance:
significantly shorter clinical trial size and duration required
Hard endpoints versus surrogate endpoints
Endpoints in weeks not years

Introducing DMX-700 for COPD

- DMX-700 for the treatment of COPD by blocking heteromer signalling in receptors active in COPD
- Initial studies on the receptor pair have been conducted under an Innovation Connections grant awarded to Dimerix in November 2018
- The two molecules working together, each with an established safety profile
- Provisional patent application filed; additional applications anticipated

New Chemical Entity
Attracting 5 year exclusivity



Actual molecules & receptor targets remain confidential pending stage 1 data & additional patent submissions

Timeline to clinic
~2 years


DMX-700 proposed mechanism of action

Certain lung cells express both receptors, thus blocking only one receptor does not block signalling and results in only a partial response to treatment

DMX-700 blocking both receptors simultaneously to provide a more complete response to treatment



DMX-700 pre-clinical data



When both Receptor ligands administered
More than additive signal observed

When only Receptor 2 ligand administered:
larger signal observed

When only Receptor 1 ligand administered:
signal observed

DMX-700 targets blocking both receptors simultaneously in cells co-expressing receptors 1 and 2, to achieve a synergistic effect



Dimerix

Summary

A hot area for big pharma?



Little innovation in new therapies in either kidney or lung disease for over 15 years:



long and challenging clinical endpoints no longer required



acceptance of surrogate endpoints



advanced development of products in areas with little or no competition



Big pharma: more licensing and M&A activity in areas with recent FDA guidance changes



DIMERIX (ASX:DXB)

End of Presentation

